Current Report Filing (8-k)
May 04 2016 - 4:57PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
April 29, 2016
Date of
report (Date of earliest event reported)
SOLAZYME,
INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35189
|
|
33-1077078
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
|
|
225 Gateway Boulevard
South San Francisco, CA 94080
|
|
94080
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(650) 780-4777
(Registrants Telephone Number, Including Area Code)
Not Applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2 below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 1.01
|
Entry into a Material Definitive Agreement.
|
On April 29, 2016, Silicon Valley Bank
issued a standby letter of credit (SVB SLOC) in favor of Itaú Unibanco S.A. (Itaú) to support a bank guarantee issued by Itaú on behalf of Solazyme, Inc. (the Company) to the Brazilian
Development Bank in connection with the loan agreement entered into in 2013 between the Brazilian Development Bank and Solazyme Bunge Produtos Renováveis Ltda., the Companys joint venture with Bunge Global Innovation, LLC and certain of
its affiliates. Upon the issuance of the SVB SLOC, approximately $12.6 million was pledged by the Company as collateral (the Collateral) to secure the issued SVB SLOC and is subject to a Standby Letter of Credit Agreement (the SLOC
Agreement) and a Bank Services Pledge Agreement (the Pledge Agreement) between Silicon Valley Bank and the Company. Pursuant to the Pledge Agreement, the Company may not pledge, assign, transfer or dispose of the Collateral, or
create or permit to exist any security interest or other encumbrance of the Collateral other than in favor of Silicon Valley Bank. In addition, the SVB SLOC is being supported by a bank confirmation issued by the Bank of Nova Scotia (the
Scotia Bank Confirmation) in favor of Itaú on behalf of Silicon Valley Bank. The Company will pay fees of 1.5% and 0.7% of the Collateral per annum related to the SVB SLOC and the Scotia Bank Confirmation, respectively. Solazyme
Brasil Oleos Renovaveis E Bioprdutos Ltda., a wholly owned subsidiary of the Company, will pay a fee of 1.99% of the Collateral per annum to Itaú for the issuance of the bank guarantee to the Brazilian Development Bank. The Company is subject
to customary events of default under each of the Pledge Agreement and the SLOC Agreement.
The letter of credit issued by Silicon Valley
Bank is intended to replace a letter of credit issued by HSBC Bank, USA, National Association (the HSBC LOC) in 2013. The Company expects the HSBC LOC to be terminated in May 2016.
The Company expects to enter a loan and security agreement with Silicon Valley Bank in the second quarter of 2016 to replace the Pledge
Agreement.
Item 2.02.
|
Results of Operations and Financial Condition.
|
On May 4, 2016, Solazyme, Inc. (the
Company) issued a press release announcing the Companys financial results for the quarter ended March 31, 2015 and certain corporate highlights. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on
Form 8-K and is incorporated herein by reference.
Item 2.03.
|
Results of Operations and Financial Condition.
|
The information set forth in Item 1.01
of this Current Report on Form 8-K is incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
The following exhibit is furnished herewith:
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press release, dated May 4, 2016, entitled TerraVia Reports First Quarter Results.
|
The information contained in Items 2.02 and 9.01 and in the accompanying exhibit shall not be incorporated by
reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in Items
2.02 and 9.01 of this report, including the exhibit hereto, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SOLAZYME, INC.
|
|
|
|
|
Date: May 4, 2016
|
|
|
|
By:
|
|
/s/ Tyler W. Painter
|
|
|
|
|
|
|
Tyler W. Painter
|
|
|
|
|
|
|
Chief Operating Officer and Chief Financial Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press release, dated May 4, 2016, entitled TerraVia Reports First Quarter Results
|